Triazine dimers for the treatment of autoimmune diseases
US7683061B2 · kind B2 · utility
2Cited by
4References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 22, 2004 |
| Grant date | Mar 23, 2010 |
| Priority date | — |
| Expiry date | Jun 22, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D251/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.